

## EQA round: APLA1/24 - Antiphospholipid Antibodies

Deadline: 15.3.2024

Setup: groups - M (measurement principle)

AV = assigned value

N<sub>tot</sub> = total number of the resultsN<sub>eva</sub> = number of the results assessed

CVP = consensus of all participants

N<sub>rel</sub> = relative number of the resultsN<sub>suc</sub> = number of successful results

&gt;&gt;&gt; ... expected result

S<sub>rel</sub> = relative success

&gt; ... acceptable result

± ... result not assessed

Test Sample Group	Frequency of the results					Success		
	AV	N <sub>tot</sub>	N <sub>rel</sub> [%]	Result	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub> [%]	
<b>(465) anti-β2-glycoprotein 1 screening</b>		13			13	13	100	
<b>Sample A</b>		13			13	13	100	
(2) EIA (ELISA)	CVP >>>	12	92	Negative				
(4) LIA (CLIA, CMIA, ECLIA, LOCI)	CVP >>>	1	7,7	Negative				
<b>Sample B</b>		13			13	13	100	
(2) EIA (ELISA)	CVP >>>	12	92	Positive				
(4) LIA (CLIA, CMIA, ECLIA, LOCI)	CVP >>>	1	7,7	Positive				
<b>(467) anti-β2-glycoprotein 1 IgG</b>		60			60	59	98	
<b>Sample A</b>		60			60	60	100	
(2) EIA (ELISA)	CVP >>>	37	62	Negative				
(3) FIA (FEIA, TRACE)	CVP >>>	5	8,3	Negative				
(4) LIA (CLIA, CMIA, ECLIA, LOCI)	CVP >>>	18	30	Negative				
<b>Sample B</b>		60			60	59	98	
(2) EIA (ELISA)		1	1,7	Negative				
	CVP >>>	36	60	Positive				
(3) FIA (FEIA, TRACE)	CVP >>>	5	8,3	Positive				
(4) LIA (CLIA, CMIA, ECLIA, LOCI)	CVP >>>	18	30	Positive				
<b>(468) anti-β2-glycoprotein 1 IgM</b>		59			59	58	98	
<b>Sample A</b>		59			59	59	100	
(2) EIA (ELISA)	CVP >>>	36	61	Negative				
(3) FIA (FEIA, TRACE)	CVP >>>	5	8,5	Negative				
(4) LIA (CLIA, CMIA, ECLIA, LOCI)	CVP >>>	17	29	Negative				
(99) Another measurement principle	CVP >>>	1	1,7	Negative				
<b>Sample B</b>		59			59	58	98	
(2) EIA (ELISA)		1	1,7	Negative				
	CVP >>>	35	59	Positive				
(3) FIA (FEIA, TRACE)	CVP >>>	5	8,5	Positive				
(4) LIA (CLIA, CMIA, ECLIA, LOCI)	CVP >>>	17	29	Positive				
(99) Another measurement principle	CVP >>>	1	1,7	Positive				
<b>(461) anti-cardiolipin screening</b>		15			15	15	100	
<b>Sample A</b>		15			15	15	100	
(0) Not specified	CVP >>>	1	6,7	Negative				
(2) EIA (ELISA)	CVP >>>	13	87	Negative				
(4) LIA (CLIA, CMIA, ECLIA, LOCI)	CVP >>>	1	6,7	Negative				
<b>Sample B</b>		15			15	15	100	
(0) Not specified	CVP >>>	1	6,7	Positive				
(2) EIA (ELISA)	CVP >>>	13	87	Positive				
(4) LIA (CLIA, CMIA, ECLIA, LOCI)	CVP >>>	1	6,7	Positive				
<b>(463) anti-cardiolipin IgG</b>		64			64	64	100	
<b>Sample A</b>		64			64	64	100	
(2) EIA (ELISA)	CVP >>>	39	61	Negative				
(3) FIA (FEIA, TRACE)	CVP >>>	5	7,8	Negative				
(4) LIA (CLIA, CMIA, ECLIA, LOCI)	CVP >>>	19	30	Negative				
(99) Another measurement principle	CVP >>>	1	1,6	Negative				
<b>Sample B</b>		64			64	64	100	
(2) EIA (ELISA)		>	6	9,4	Negative			
	CVP >>>	33	52	Positive				
(3) FIA (FEIA, TRACE)		>	3	4,7	Negative			
		>	1	1,6	Inconclusive result (borderline)			
	CVP >>>	1	1,6	Positive				
(4) LIA (CLIA, CMIA, ECLIA, LOCI)	CVP >>>	19	30	Positive				
(99) Another measurement principle	CVP >>>	1	1,6	Positive				
<b>(464) anti-cardiolipin IgM</b>		63			63	63	100	
<b>Sample A</b>		63			63	63	100	
(2) EIA (ELISA)	CVP >>>	39	62	Negative				
(3) FIA (FEIA, TRACE)	CVP >>>	5	7,9	Negative				
(4) LIA (CLIA, CMIA, ECLIA, LOCI)	CVP >>>	19	30	Negative				
<b>Sample B</b>		63			63	63	100	
(2) EIA (ELISA)	CVP >>>	39	62	Positive				
(3) FIA (FEIA, TRACE)	CVP >>>	5	7,9	Positive				
(4) LIA (CLIA, CMIA, ECLIA, LOCI)	CVP >>>	19	30	Positive				